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Abstract 
(304 words) 
 
Background: Previous studies suggest circulating, blood-based microRNAs (miRNAs) may 
serve as minimally invasive prostate cancer biomarkers, however there is limited data from 
prospective clinical trials. Here, we explore the role of candidate plasma miRNAs as potential 
biomarkers in the SWOG 0925 randomized phase II study of androgen deprivation combined 
with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-
sensitive prostate cancer.  
 
Methods: Correlative biospecimens, including circulating tumor cells (CTCs) and plasma for 
miRNA analysis, were collected at baseline and after 12 weeks on treatment from 50 patients 
enrolled on SWOG 0925. Circulating microRNAs were quantified using real time RT-PCR 
microRNA array that allowed specific analysis of previously identified candidate miRNAs (miR-
141, miR-200a, miR-200b, miR-210 and miR-375) as well as discovery analysis to identify new 
candidate miRNAs. MiRNA levels were correlated to previously reported CTC counts using 
CellSearch (Veridex) and with the primary study outcome of 28-week PSA response (≤0.2, 0.2 
to ≤4.0, or >4.0 ng/mL), previously shown to correlate with overall survival.  
 
Results: We observed a correlation between baseline circulating miR-141, miR-200a, and miR-
375 levels with baseline CTCs. Baseline miR-375 levels were associated with 28-week PSA 
response (≤0.2, 0.2 to ≤4.0, or >4.0 ng/mL, P=0.007). Using ROC curve analysis, there was no 
significant difference between baseline miR-375 and baseline CTC in predicting 28-week PSA 
response (≤0.2 vs. >0.2 ng/mL). To discover novel candidate miRNAs, we analyzed 365 
miRNAs for association with the 28-week PSA response endpoint and identified new candidate 
miRNAs along with the existing candidates miR-375 and miR-200b (P=0.0012, P=0.0046, 
respectively. 
 
Conclusions: Baseline plasma miR-141, miR-200a, and miR-375 levels are associated with 
baseline CTC count. Baseline miR-375 was also associated with the trial endpoint of 28-week 
PSA response. Our results provide evidence that circulating miRNA biomarkers may have value 
as prognostic biomarkers and warrant further study in larger prospective clinical trials.   
 
KEY WORDS: circulating, microRNA, prostate cancer, miR-375, miR-200, miR-141 
 
WORD COUNT: 2533 
 
RUNNING TITLE: Circulating miRNAs in SWOG 0925 
INTRODUCTION:  
Therapeutic options for advanced prostate cancer have changed dramatically in the past 
decade[1, 2]. Better prognostic and predictive biomarkers are needed to address the clinical 
challenges of appropriate selection and sequencing of the range of new treatment options. Earlier 
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work demonstrated the prognostic value of circulating tumor cells and led to FDA approval of 
CTC enumeration to aid in prognosis of men with metastatic castration resistant prostate 
cancer[3, 4]. Additional studies have indicated the potential value of assessing expression of the 
androgen receptor splice variant 7 (AR-V7) in circulating tumor cells in the castration resistant 
setting[5]. However, the lower sensitivity of CTC detection has been an issue, for example, less 
than half of men in SWOG 0925 had CTCs at baseline[6]. Identifying better prognostic and 
predictive biomarkers therefore remains a largely unmet need.  
Circulating, blood-based microRNAs (miRNAs) are similar to circulating tumor cells 
(CTCs) in that they serve as promising, minimally invasive prostate cancer biomarker 
candidates[7-11]. MiRNAs are short (~22 nucleotide) non-protein encoding RNAs that play an 
important role in regulation of gene expression via modulation of specific messenger RNA 
(mRNA) targets[12]. A single miRNA may regulate hundreds to thousands of mRNA transcripts 
and therefore may summarily reflect biological gene expression networks and provide 
complementary biological information to CTCs. MiRNAs may also be more sensitive and simple 
to assay than CTCs.  
To explore the possibility that miRNAs may be more sensitive and easier to assay that 
CTCs and to see if miRNAs are predictive of PSA outcomes at 28 weeks, we prospectively 
collected correlative biospecimens on the randomized Phase II SWOG 0925 clinical trial8. We 
previously reported findings on CTCs and IGF-1R biomarkers, along with association to the 
primary endpoint of PSA after 28 weeks of therapy. To briefly summarize, of 50 patients that 
provided CTC samples, 39 had evaluable results and 16/39 (41%) had no detectable CTCs 
despite being collected from a population of patients with newly diagnosed metastatic prostate 
cancer.   
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Here, we report the results of our biomarker analysis of circulating miRNA in association 
with CTCs as well as with the primary endpoint of the clinical trial: PSA at 28 weeks, an 
outcome previously shown to correlate with overall survival[13]. We focused on 5 candidate 
circulating miRNAs which were previously identified via miRNA profiling and validated to be 
elevated in prostate cancer cases compared to controls: miR-141, miR-200a, miR-200b, miR-210 
and miR-375[7]. In addition, we used a wider profiling approach in which we examined plasma 
levels of 365 miRNAs to identify candidates whose baseline levels associated with the study 
endpoint of 28-week PSA as novel prognostic biomarker candidates.  
 
PATIENTS AND METHODS: 
Patients.  
The randomized, Phase II SWOG S0925 study investigated androgen deprivation (AD) 
combined with cixutumumab versus AD alone in patients with new metastatic hormone-sensitive 
prostate cancer (ClinicalTrials.gov NCT01120236) has previously been described[6]. The results 
of the study did not show a significant difference in outcome between the two treatment arms, so 
we considered the patients in both arms in aggregate for the purpose of biomarker analyses. 
Eligible patients for the miRNA analysis were patients enrolled in SWOG 0925, had pathologic 
confirmation of prostate cancer, PSA ≥5 ng/mL, and at least one radiographic detectable 
metastasis and had not yet started any form of AD. Fifty patients consented to the biomarker 
specimen collection and participated in the biomarker sub-study. All study procedures were 
performed in accordance with the declaration of Helsinki guidelines and with ethics approval 
from the Institutional Review Boards at participating SWOG sites.  
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Blood processing and isolation of plasma and CTCs from clinical samples.  
Plasma and CTCs were collected prior to initiation of AD and again at 12 weeks from 50 
patients enrolled in the SWOG 0925 translational science substudy. Plasma samples designated 
for circulating miRNA analysis were collected into Becton Dickinson lavender top vacutainer 
tubes containing K2EDTA. Whole blood (7.5ml) was collected for Cellsearch circulating tumor 
cells assessment (Veridex, Raritan, NJ). All clinical samples obtained were collected and 
processed locally as previously described[7] and then shipped to the Fred Hutchinson Cancer 
Research Center within 24 hours of blood draw. Briefly, upon arrival, plasma samples were 
centrifuged at 3000xg for 5 minutes at room temperature to separate the plasma, aliquoted into 
cryovials and stored at -80C. CTC measurements were performed using the clinical CellSearch 
platform (Veridex). Both timepoints from a single patient were ex racted and run in the same 
batch to minimize batch effect. 
 
Quantification of circulating miRNAs.  
Total RNA was isolated from 200ul plasma using the miRNeasy RNA isolation kit 
(Qiagen, Germany) in the following manner: Frozen aliquots were thawed on ice, centrifuged at 
3000xg for 3 minutes at room temperature to remove additional cellular debris and insoluble 
components[28], and 200 µl of plasma supernatant was measured and denatured using 10X 
volume (1 ml) Qiazol, vortexed and incubated at room temperature for 10 minutes. C. elegans 
spiked-in oligonucleotides were introduced (as a mixture of 25 fmol of each oligonucleotide in 5 
µl total volume per liquid sample) after denaturation, which were used for normalization of 
variability in RNA isolation across samples as previously described[7]. RNA was extracted using 
0.2X volume chloroform (220 µl), and total RNA was isolated following the manufacturer’s 
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protocol. For a given sample, RNA isolated from each 200 µl aliquot was eluted using 50µl 
RNAse-free water at 1000xg, 3 min, 4oC. RNA was stored at -70oC.  
Reverse transcription was performed in triplicate then pooled (to minimize batch effect) 
using 13 µl of RNA as input for the MirCURY Exiqon Universal RT kit following 
manufacturer’s protocol. Reaction was incubated at 42oC for 60minutes followed by 5 minutes at 
95C, transfer to non-stick tubes and stored at -20C. Complementary DNA was then combined 
with SYBR Green Master mix, ROX and 10 µl was aliquoted into each well of a miRNA Ready-
to-Use PCR, Human panel I, V1.M qRT-PCR array (Exiqon). Each sample was run in duplicate. 
 
miRNA Detection and Normalization 
Missing (i.e., Undetermined) raw cycle threshold (Ct) values were set to 40 (the
 
highest 
possible raw Ct value in the data). Any miRNA targets with a Ct value of 40 in 60% or more of 
the samples were filtered out before the normalization and excluded from further analysis. A 
total of 280 (out of 375) miRNA targets passed the filtering. The raw Ct values for all the 280 
miRNA targets were then quantile normalized (using R function "normalize.quantiles") across all 
the samples.  
The average coefficient of variation was 4.0% (range: 1.1-9.8%) for all miRNAs and 
5.6% (range: 3.2-8.0%) for the 5 previously validated miRNAs. 
 
Study population and evaluable samples. 
Fifty patients participated in the translational science biomarker sub-study (patient 
demographics shown in Table 1). Among these patients, 1 patient was ineligible for the trial, 6 
patients initiated LHRH therapy prior to registration, and 3 patients lacked available samples for 
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miRNA analysis. MiRNA data from the 40 remaining eligible and analyzable patients were used 
in these analyses. Baseline CTCs were collected for all 40 patients mentioned above, but 4 CTC 
samples were not assessable, resulting in 36 eligible patients for the baseline CTC analysis.   
 
Statistical Considerations: 
The Friedman test was used to assess correlations between the five previously validated, 
normalized miRNA data as ranks (due to lack of normally distributed data) and categories of 
baseline CTC counts, and normalized miRNA data and PSA response categories at 28 weeks 
after registration. This nonparametric method accounts for the ordinal nature of baseline CTC 
categories (0, 1-4, ≥ 5 CTC count per 7.5mL whole blood) and PSA response categories 
(PSA≤0.2, 0.2<PSA≤4.0, PSA>4.0 ng/mL). A significance level for these validated analyses was 
specified as ≤ 0.05. 
 In addition to the five previously identified candidate miRNA markers, we performed a 
wider miRNA profiling analysis to potentially identify additional miRNAs that may be 
correlated with baseline CTC categories and/or 28-week PSA response category. Following 
quantile normalization, an additional 275 miRNAs were analyzed using the same Friedman test. 
A Bonferroni correction (0.05/275 = .00018) could be used as a guideline for evaluating 
statistical significance, but if miRNA are correlated, this approach would be overly conservative. 
 
RESULTS:  
Correlation of five previously validated baseline miRNAs (CTs) and baseline CTC counts.  
We first examined whether baseline assessments of any of the five candidate circulating 
miRNAs are associated with baseline CTC counts (Table 2). There was an association between 
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baseline CTC counts and baseline circulating miR-141 (P=0.0006), but not with baseline levels 
of the other four, miR-200a, miR-200c, miR-210 or miR-375. 
 
Correlation of five previously identified baseline miRNA and 28-week PSA response 
categories. 
We examined whether baseline assessments of any of the five candidate circulating 
miRNAs are associated with 28-week PSA response (Table 3), the primary outcome of the 
clinical study, and thus serve as a prognostic biomarker at time of starting treatment. We 
observed a significant association between 28-week PSA response categories (PSA≤0.2 ng/mL, 
0.2<PSA≤4.0 ng/mL, PSA >4.0 ng/mL) and circulating miR-375 (p=0.001) and miR-200b 
(p=0.005). In contrast, we did not observe a significant association between 28-week PSA 
response categories and miR-141 (P=0.06), miR-200a (P=0.32), or miR-210 (P=0.59).  
 
Analysis to identify novel miRNA candidates.  
Following quantile normalization, we evaluated whether the miRNAs may be associated 
with baseline CTCs. The candidate miRNAs that are most strongly correlated with CTC 
categories are listed in Table 2 and those most correlated with 28-week PSA response categories 
are listed in Table 3. All miRNAs are associated with baseline CTC and PSA response in 
Appendix Tables A and B).  
 
DISCUSSION: 
In this companion translational biomarker sub-study to the prospective randomized, 
Phase II SWOG 0925 study, we report our findings examining circulating miRNA biomarkers 
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for treatment response prediction in a multi-center cooperative group clinical trial. This is an 
important step in demonstrating feasibility of miRNA assessment in the broader context of 
clinical practice.  
Analysis from the SWOG 9346 clinical trial demonstrated that PSA at 7-months (28-
week) is prognostic for overall survival in men with newly diagnosed hormone sensitive 
metastatic prostate cancer[13] and therefore served as the primary endpoint for SWOG 0925. 
Here we also evaluated the correlation of baseline circulating miRNA with the primary endpoint 
to determine if similar prognostic information could be gleaned at the start of initiation with AD 
and before the 7 months (28-week) timepoint. We found that baseline circulating miR-375 was 
associated with 28-week PSA, in both the candidate analysis and the discovery analysis. That we 
found the association through both analyses lends greater confidence in the results.  
Multiple studies have identified miR-375 as elevated in advanced prostate cancer tumors, 
in circulating blood[11, 14, 15] and in urine[16]. Recent work suggests that miR-375 is involved 
in the epithelial-mesenchymal-transition (EMT) signature [17], and that disruption of this 
regulatory network may result in altered expression of miR-375. Another recent report suggests 
miR-375 mediated repression of the tumor suppressor CBX7, a member of the Polycomb 
complex involved in epigenetic regulation, which may be associated with prostate 
tumorigenesis[18]. 
We sought to explore candidate miRNAs that we previously identified through 
differential examination of blood samples from metastatic prostate cancer patients and healthy 
controls, miR-141, miR-200a, miR-200c, miR-210, miR-375. It is possible that this approach 
could miss some candidate miRNAs and indeed following the discovery analysis, we identified a 
number of additional potential candidate miRNAs to be considered for further investigation 
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(Tables 2 and 3). Given that the numbers of patients were relatively small (approximately 34-40) 
and the number of miRNAs evaluated in parallel was substantially greater (365), we are cautious 
about overinterpreting the significance of these candidate miRNAs without further studies. Since 
the number of miRNAs evaluated was large, it is possible that a fraction were calculated to be 
significant by chance (i.e. false positive). However, through simple mathematical calculation, we 
would expect about three from the discovery list to be significant and represent true positives. 
Further study will be needed for validation.  
In reviewing the list of candidates identified through discovery analysis, some have been 
reported in the literature previously, either in association with biological processes such as in 
vitro studies, or in studies specifically to identify new prostate cancer biomarkers. It is interesting 
that the miR-200 family (especially miR-141) correlates with CTCs. The miR-200 family has 
been identified in other studies, and evidence suggests a role in the EMT[7]. A recent study 
suggests miR-141 may have multiple mechanisms for affecting tumor growth and 
metastases[19]. Another Phase 2 study of circulating miRNAs in patients with metastatic 
castration resistant prostate cancer treated with docetaxel identified miR-200 family 
members.[20]  
We and others have reported that miR-375 is elevated in plasma of CRPC patients[11, 
21-23]. It is noteworthy that miR-375 is also made by non-prostate tissues including endocrine 
tissues[24], and it is therefore possible that expression of miR-375 may reflect a tissue state 
affecting treatment response independent of CTCs. We are encouraged to find that miR-375 has 
also been reported in both plasma and urine from patient studies[16, 25]. Our findings add to the 
evidence that circulating miR-375 warrants further study in prospective clinical trials. 
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We previously reported on CTC enumeration using the CellSearch platform from this 
study as a prognostic biomarker and here we have compared miRNA assessments to CTCs in 
order to explore if miRNAs may potentially be similar to, more sensitive than and/or provide 
complementary data to CTCs. Our sample size was limited by smaller numbers of patients 
eligible due to the requirement for not have initiated AD at start of biomarker substudy. 
Moreover, only 59% of patients had a measureable CTC count at baseline, thus limiting our 
ability to do statistically rigorous comparisons between CTCs and miRNAs. Nevertheless, we 
found that of the 5 candidate miRNAs, baseline miR-141, miR-200a, and miR-375 appear to be 
correlated with baseline CTC counts, suggesting that circulating miRNA and CTCs may be 
released following the same or linked biological mechanisms and/or that circulating miRNAs 
may be released from CTCs. While more investigations will be needed to further explore 
whether circulating miRNAs may be more sensitive that CTCs detected by CellSearch, we 
recognize that there is also ongoing work around improving the sensitivity of CTC enumeration 
as well as specific molecular assessments of CTCs[26, 27].  
In conclusion, we evaluated circulating miRNAs from the SWOG 0925 clinical trial in 
which 41% of patients had baseline CTC = 0. We found association between candidate miRNAs 
miR-141, miR-200a, miR-200c and miR-375 levels were significantly correlated with the 
stratified baseline CTCs as enumerated by CellSearch, but the sample sizes were insufficient to 
determine whether circulating miRNAs may be more sensitive. Baseline miR-375 level and 
baseline CTC count were associated with the primary endpoint of 28-week PSA, providing the 
potential for prognostication at time of initiating AD. Finally, our discovery analysis identified 
novel potential candidate miRNAs, but more investigation is needed for confirmation.  
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Eventual survival outcomes from SWOG 0925 will be enlightening, and if our observation 
holds true in additional studies, baseline circulating miR-375 in combination with other clinical 
factors and biomarkers could serve to further stratify patients for future clinical trials and/or 
more intensified therapies. This works substantially adds to evidence for the role of circulating 
miRNAs as prostate cancer prognostic biomarkers.  
 
FIGURE LEGENDS: 
 
Figure 1. SWOG 0925 Trial Schema with Translational Biomarkers.  
*Patients were not eligible for the translational miRNA and CTC analysis unless they had 
received no prior androgen deprivation (AD). LHRH – Luteinizing hormone releasing hormone. 
CTCs – circulating tumor cells. miRNAs – microRNAs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Based on 2 degree of freedom chisquare, Friedman test 
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Table 3. Correlation of Baseline miRNAs (CTs) with 28-week PSA Response Categories 
for All Prespecified miRNA measures and Exploratory miRNA with p< 0.10 
 
miRNA Median miRNA value for Each PSA response 
group 
p-
value* 
 PSA ≤ 0.2  0.2< PSA≤4.0 PSA > 4.0 ng/ml  
miR-141 32.6 32.0 31.5 0.06 
miR-200a 34.5 33.8 33.8 0.32 
miR-200b 33.6 33.6 32.6 0.005 
miR-210 32.5 32.1 32.3 0.59 
miR-375 33.0 32.6 29.5 0.001 
                   Additional exploratory miRNA candidates 
hsa-miR-505 32.1 32.6 31.9 0.004 
hsa-miR-136 32.3 30.5 32.9 0.009 
hsa-miR-204 34.6 36.2 35.0 0.02 
hsa-miR-99a 32.7 34.6 32.4 0.02 
hsa-miR-130a 32.3 31.4 31.7 0.02 
hsa-miR-10a 35.3 37.4 35.6 0.03 
hsa-miR-450a 35.9 39.6 36.8 0.03 
hsa-miR-376b 30.8 29.5 31.5 0.03 
hsa-miR-376c 30.7 29.1 31.4 0.034 
hsa-miR-431 33.4 31.8 33.8 0.04 
hsa-miR-381 35.5 34.3 36.3 0.04 
hsa-miR-671-5p 34.8 34.3 33.5 0.05 
hsa-miR-376a 32.4 30.7 32.4 0.05 
hsa-miR-411 33.8 33.3 34.9 0.05 
hsa-miR-125b 31.4 31.6 31.1 0.06 
hsa-miR-370 34.3 32.9 34.3 0.06 
hsa-miR-127-3p 31.6 30.3 32.1 0.06 
* Based on 2 degree of freedom chisquare, Friedman test 
 
 
Supplementary Figure 1: 1A. Scatterplot Display of miRNAs (CTs) with Significant 
Associations with 28-week PSA Response Category. 1B. Scatterplot of miRNA (CTs) with 
Significant Association with Baseline CTC Count Category 
 
Supplementary Tables 1A and 1B: All miRNAs w/ p-values  
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Table 1. Patient Characteristics of all Eligible Patients 
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Table 2. Correlation of Baseline 
miRNAs (CTs) with Baseline 
Circulating Tumor Cell Categories 
for All Prespecified miRNA measures 
and Exploratory miRNA with p< 
0.10 
miRNA Median miRNA for Each CTC group p-value* 
 CTC=0 CTC = 1-4 CTC= 5+  
miR-141 32.9 32.7 31.9 0.0006 
miR-200a 34.4 34.7 33.0 0.23 
miR-200b 33.4 33.2 33.6 0.52 
miR-210 32.5 32.7 32.1 0.39 
miR-375 32.8 32.7 30.2 0.13 
Additional exploratory miRNA candidates 
miR-188-5p 34.5 37.1 34.4 0.02 
miR-885-5p 33.2 36.0 34.1 0.04 
miR-429 36.7 34.3 33.5 0.04 
miR-135a 33.5 33.6 34.2 0.04 
miR-483-3p 37.2 37.8 39.5 0.05 
miR-190 35.2 34.5 34.5 0.05 
miR-370 34.6 33.9 33.0 0.05 
 N % 
AGE 40  
   Median, (range)  68 (50, 85)  
RACE   
   White 36 90%  
   Black 2 5%  
   Other 2 5%  
Zubrod PS   
   0-1 40 100% 
   2 0 0% 
GLEASON SCORE   
   <7 3 8% 
   7 7 18% 
   >7 30 74% 
PSA AT ENTRY (ng/ml)   
   < 20 ng/mL 11 28% 
   ≥ 20 ng/mL 29 72% 
Treatment Arm   
Arm 1 - cixutumumab + ADT 24 60% 
Arm 2 – ADT alone 16 40% 
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miR-299-5p 35.0 35.7 33.7 0.06 
miR-199b-5p 32.1 31.7 32.5 0.06 
miR-570 35.1 35.0 36.5 0.07 
 
